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2214-3882/ª 2015 Editorial Office of A
article under the CC BY-NC-ND licenseAbstract Benign prostatic hyperplasia (BPH) is a condition that occurs increasingly with age.
The established gold standard treatment for BPH has been the electrocautery-based transur-
ethral resection of the prostate (TURP). TURP, however, is associated with several complica-
tions and side effects. Therefore, there is an increasing interest in a number of emerging
minimally invasive therapies as alterative treatment options. Laser therapy using the Green-
light laser is a promising alternative to the traditional TURP. Selective absorption by hemoglo-
bin allows rapid, hemostatic vaporization of prostate tissue. Additional advantages include
avoidance or minimization of complications such as intraoperative fluid absorption, and
bleeding, retrograde ejaculation, impotence, and incontinence, as well as its use in treating
high volume BPH. We review the use of the Greenlight laser in the treatment of BPH, when
comparing complications and advantages in relation to TURP.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Theestablished gold standard treatment for benign prostatic
hyperplasia (BPH) has been the electrocautery-based tran-
surethral resection of the prostate (TURP). TURP, however, isell.edu (B. Chughtai).
f Chinese Urological Associa-
.04.021
sian Journal of Urology. Productio
(http://creativecommons.org/liassociated with several complications and side effects.
Therefore, there is an increasing interest in a number of
minimally invasive therapies as alterative treatment op-
tions. Laser therapy using the Greenlight laser has shown
promising alternative to the traditional TURP. The greenlight
allows for selective absorption by hemoglobin and hemo-
static vaporization of prostate tissue. Other advantages
include avoidance or minimization of complications such as
intraoperative fluid absorption, and bleeding. An additional
benefit of laser therapy may be shorter hospital stay andn and hosting by Elsevier (Singapore) Pte Ltd. This is an open access
censes/by-nc-nd/4.0/).
532 nm laser for treatment of BPH 103recovery time in comparison to TURP. Laser prostatectomy
also has allowed for the treatment of larger prostate glands
with a reduced risk of complications.
2. Evolution of 532 nm wavelength laser
2.1. In vitro studies
The first experiments with the higher powered (80 W) po-
tassium titanyl phosphate (KTP) laser began with the use of
ex-vivo animal models [1]. Twenty perfused porcine kidneys
were used as a model for human prostatic tissue. High
power KTP laser resection was compared to high frequency
current, i.e., TURP-like, resection. The 80 W KTP laser
technique showed a statistically significant decrease in
hemorrhage (p < 0.0001) compared to traditional TURP-like
resection, demonstrating the fact that an essentially
bloodless operative field could be achieved.
In addition several animal studies have been performed
with the 120 W 532 nm laser. Lee et al. [2] investigated the
use of the 120 W laser in five male beagles. The 120 W laser
system was compared to lower watt settings, the 120 W
setting vaporized more tissue per unit time while main-
taining a depth of coagulation between 1.2 and 2.5 mm.
Kang et al. [3] compared the use of the 120 W high-
performance system (HPS) laser to the 80 W HPS laser and
the 80 W KTP laser from 96 specimens of bovine prostate
tissue. The 120 W HPS laser vaporized bovine prostate tis-
sue more efficiently than the 80 W KTP laser and coagula-
tion was equivalent.
2.2. Human studies
2.2.1. Safety studies
The safety of the 80 W KTP laser prostatectomy has been
studied in patients with high cardiopulmonary risk. Reich
et al. [4] performed 80 W laser prostatectomy on 66 pa-
tients with an American Society of Anesthesiologists (ASA)
Score of 3 or greater. Of these patients, 29 were being
treated with ongoing oral anticoagulation or suffered from
a severe bleeding disorder. No major complications
occurred during or following the procedure and no blood
transfusions were required.
Another safety aspect of the 80 W KTP laser to be
studied in detail was its use in anticoagulated patients. A
series of 24 anticoagulated patients who underwent a laser
prostatectomy using the 80 W KTP laser were studied [5].
No patients developed clinically significant hematuria
postoperatively and none developed clot retention. No
transfusions were required and there were no thrombo-
embolic events that followed the procedure. Few studies
have been published on the safety and efficacy of the 120 W
532 nm laser prostatectomy in humans. In a multi-center
prospective study, 305 patients with BPH underwent laser
prostatectomy with the 120 W HPS laser [6]. Complication
rates of those on anticoagulation were comparatively low
to those not on anticoagulation, although this population
had many patients with large volume glands and or had
signs and symptoms of urinary retention.
An advantage to the use of the 80 W KTP/532 nm laser is
the ability for the surgeon to perform laser prostatectomyon larger glands with good outcomes and an excellent
safety profile. Sandhu et al. [7] detailed large prostate
volume resection with the 80 W KTP laser. Sixty-four men
with prostate volumes of at least 60 mL and had failed
medical therapy previously were taken for vaporization
with the 80 W KTP laser. The mean preoperative prostate
volume was 101 mL with a mean operative time of 123 min.
International Prostate Symptom Score (IPSS) decreased
from 18.4 to 6.7 at 12 months; maximum flow rate (Qmax)
increased from 7.9 mL/s to 18.9 mL/s while postvoid urine
residual (PVR) decreased from 189 mL to 109 mL. No
transfusions were required throughout the procedure nor
was there evidence of postoperative hyponatremia. All 62
patients were discharged within 23 h. This study showed
that the 80 W KTP laser could be used as a safe and
effective means with durable results for large volume
prostatectomy.
In a comparative study performed by Pfitzenmaier et al.
[8], vaporization was performed on prostates with volumes
greater than or equal to 80 mL and on those with volumes
smaller than 80 mL. Out of 173 patients, 39 had prostates
80 mL. The authors found that the use of photoselective
vaporization prostatectomy (PVP) was safe and effective in
prostates  80 mL; however, they also found that the
reoperation rate was higher. In another recent study of 150
consecutive patients with lower urinary tract symptoms
who underwent laser vaporization with 80 W KTP laser
showed a decrease in storage and voiding symptoms by
81.8% and 90.9% at 12 months, respectively [9]. Consistent
with other published series, these studies further support
the safety, efficacy, and durable improvements on IPSS and
quality of life (QoL) of the procedure [7].
While many studies have reviewed the efficacy and
outcomes of the 80 W KTP laser, few have reviewed the
newer 120 W Greenlight HPS lithium triborate laser. Batura
et al. [10] investigated the nature and frequency of com-
plications that are associated with this newer approach. In
their study, complications due to the procedure developed
in 15.4% of patients over and average follow up time of 20.8
months; urethral strictures and obstruction due to residual
prostate tissue were the most frequent complications, at a
rate of 3.4% and 4.3% respectively. In addition, their study
found an 84% success and durable outcome at 2 years of
follow-up. At their center they found that patients who
received TURP had an average length of stay and duration
of catherterization of 2.5 days each, whereas those
observed with laser treatment had stays and catherteriza-
tions that lasted 1 day each [10].
High intraoperative safety has been demonstrated for
the 120-W LBO-laser with an intraoperative bleeding rate of
1%e2.6%, capsule perforation in 1%, intraoperative blood
transfusion in 0.4% and no TUR syndrome reported [11].
The GOLIATH study conducted by Bachmann et al. [12]
compared the safety and efficacy of TURP vs. the 180 W
XPS GreenLight laser over a 6-month period. Overall 47.8%
of patients who received laser treatment compared to
53.4% of patients that received TURP were free of treat-
ment related adverse events. Whereas with earlier laser
systems, the reintervention rate was higher when
compared to TURP, the GOLIATH study showed that overall
numbers of patients free of any adverse events were
comparable between these two methods. The two
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104 B. Chughtai et al.treatment arms were similar with respect to reinterven-
tion; however within 30 days of treatment reintervention
was three times higher after TURP [12].
2.2.2. Clinical studies
2.2.2.1. Short-term studies. The first human trials with
the 60 W KTP laser were conducted in a series of 10 patients
described by Malek et al. [13] in 1998. Patients experienced
a significant improvement in Qmax (142%) by 24 h
postoperatively, although the follow-up was only 3
months (Table 1). This was followed by a larger series of
55 patients in 2000 [14]. The 2-year experience with the
higher powered KTP laser again corroborated initial
findings.
Hai and Malek [15] presented the first human experience
with 80 W KTP laser prostatectomy. Ten patients were
followed for 1 year after their prostatectomy in a pilot
study. Patients experienced statistically significant
improvements in AUA symptom score (23.2 to 2.6), QoL
scores (4.3 to 0.5), Qmax (10.3 to 30.7 mL/s), and PVR
(137.6 to 3 mL). Te et al. [16] presented the first large,
multicenter series on the use of 80 W KTP laser in laser
prostatectomy for 145 patients with long-term follow-up.
Significant and durable improvements in AUA Symptom
Index (AUA SI) scores, QoL scores, Qmax, and PVR were
demonstrated up to 12 months postoperatively (Table 1).
In a trial by Bouchier-Hayes et al. [17], 120 patients
were randomized to TURP or PVP. Maximum urinary flow
rate improved by 154% in the TURP and 136% in the PVP
group. Other outcomes had similar improvements in both
arms. They also found that PVP was 22% less expensive due
to decreased length of stay. Another randomized study was
done by Horasanli et al. [18] randomized 76 patients with
prostates larger than 70 mL. They found a significant dif-
ference in IPSS, Qmax, and PVR in favor of TURP and a larger
volume reduction as well. The PVP group had an 18%
reoperation rate. Although, it must be remembered that
both these studies were conducted with the 80 W KTP laser.
Ouyang et al. [19] explored the impact that the 160 W
laser had on erectile dysfunction. Patients were randomly
assigned to treatment with either the 80 W or 160 W laser,
and erectile dysfunction was evaluated based on IIEF-5. In
their study the results showed that IIEF-5 scores of the 80 W
and 160 W groups both significantly decreased at 3 month
follow-up compared to the patients pre-operative baseline;
however, by 6 and 12 months IIEF-5 scores were not
significantly different (Table 1). Ultimately, it was
concluded that the 160 W laser vaporization of the prostate
will not increase the risk of erectile dysfunction, whereas it
can greatly increase the efficiency of vaporization [19].
An important consideration is the treatment of large
prostates. Altay et al. [20] studied the 12 month safety and
efficacy of the 180 W XPS GreenLight laser with the MoXy
fiber in prostates larger than 80 mL. Sixty-eight patients
with a mean age of 71.1  9.8 were evaluated and out-
comes were assessed at 3, 6, and 12 months post-
operatively. Subjective parameters such as IPSS and IIEF-5
were assessed as were objective parameters such as Qmax,
PVR and transrectal ultrasound (TRUS) volume [20]. Mean
prostate volume was (104.3  29.7) mL with a range of
81e185 mL [20]. Significant improvements were seen in
IPSS, Qmax, and PVR (p < 0.001) at all-time points [20]. A
532 nm laser for treatment of BPH 105reduction of prostatic volume by 40.5% was seen at 12
months (Table 1). The authors concluded that the use of the
180 W GreenLight laser system was effective and safe in the
treatment of large prostates [20].
A recent study by Emara and Barber [21] reported on
their early experience with the XPS Generator and the Moxy
Laser Fiber. One hundred and thirty-one patients, with an
average age of 72.6 were treated using the XPS/MoXy sys-
tem. Subjective parameters such as IPSS as well as objec-
tive parameters such as Qmax, PVR, and prostate volume
were assessed at 3 months post-operative follow-up, and
compared to the preoperative data [21]. Patients were
divided into three groups based on preoperative prostate
size (<40 mL, 40e80 mL, >80 mL). Significant improve-
ments were seen in mean IPSS (18.51  0.8036 vs.
8.529  0.7164, p < 0.0001) and Qmax (9.843  0.4188 mL/s
vs. 20.10  1.543 mL/s, p < 0.0001) postoperatively in all
three groups [21]. Mean prostatic volume reduction was
51.2%, 49.8%, and 48.1% for all three groups respectively.
Results showed that the XPS generator and MoXy fiber are
able to achieve effective results with respect to clinical
outcome and prostatic volume reduction [21].
2.2.2.2. Long-term studies. As a novel procedure, there
are growing numbers of reports of long-term outcomes of
80 W KTP laser prostatectomy. Ruszat et al. [22] published
the largest series of 80 W KTP laser prostatectomies. At a
single center, 500 patients underwent PVP, including 45%
taking oral anticoagulation. After 3 years, 26.2% of
patients had follow-up and mean AUS SI, PVR, and QoL
were significantly improved compared to baseline. At 60
months, retreatment rate was 6.8%. Urethral and bladder
neck strictures were observed in 4.4% and 3.6% of
patients, comparable to the rate in TURP. Te et al. [16]
reported 3-year multi-center long-term follow-up in 139
patients who underwent 80 W KTP laser prostatectomy. At
3 years, 33.8% of patients had follow-up and
improvements in symptom relief and urinary flow rate
were durable. Retreatment rate was 4.3%.
Te et al. [16] presented the first large, multicenter se-
ries on the use of 80 W KTP laser in laser prostatectomy for
145 patients with long-term follow-up. Of note, this expe-
rience represented the initial laser experience of this
technology with these centers, testing its ease of use.
Significant and durable improvements in AUA Symptom
Index (AUA SI) scores, QoL scores, Qmax, and PVR were
demonstrated up to 12 months postoperatively. Mean AUA
symptom scores declined from 24 to 1.8 at 12 months; mean
QoL scores improved from 4.3 to 0.4, Qmax from 7.7 to
22.8 mL/s, and PVR volume from 114.2 to 7.2 mL. Mean
prostate volume, which was determined by ultrasound,
decreased from 54.6 to 34.4 mL (Table 1). Mean operative
time was 36 min, and no patient required a blood trans-
fusion. More than 30% of patients were sent home without a
catheter; and for those patients that did require post-
operative catheters, they had them removed in a mean
time of 14 h post-operatively. Morbidity as reported by the
doctors was generally minor. It was found that 8% of pa-
tients experienced mild-to-moderate dysuria lasting more
than 10 days, 8% had transient hematuria, and 3% had post-
operative retention. Among the 56 men who were potentprior to the procedure, 27% experienced retrograde ejac-
ulation but none of them experienced impotence.
3. Conclusions
TURP has been used as the standard of care for the treat-
ment of BPH, however complications due to its use, such as
bleeding, retrograde ejaculation, impotence and inconti-
nence, have led to a growing interest among physicians in
the use of minimally invasive therapies as alternatives to
the procedure. The Greenlight laser has shown to be
favorably comparable to the use of TURP when comparing
complication rates. Less bleeding and irrigant absorption
has theoretically also allowed laser prostatectomy to treat
larger volume glands with less physiologic stress; as such,
this suggests a role for laser therapy in patients with a high
burden of coexisting medical disease. Moreover, the use of
laser technology is generally accessible to the practicing
urologist. The transurethral endoscopic approach and
operative techniques are fairly simple. These attributes
have positioned laser prostatectomy as an accepted and
often preferred surgical treatment of BPH, perhaps one day
surpassing TURP as the gold standard of care for BPH.
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